CTLA4 and colorectal carcinoma: In the TCGA and GEO databases, patients with CRC with high-risk scores had higher expression of immunotherapeutic molecules (such as PD-L1, CTLA4, HAVCR2 and LAG3), suggesting that CRC with high-risk scores may be more likely to be affected by the immune-checkpoint pathway, inhibit the antitumor immune response, and lead to deterioration of prognosis. Similarly, the TIDE algorithm predicted that patients with high-risk scores were more sensitive to ICI therapy.